Effectiveness of immunosuppressive therapy in children with autoimmune hepatitis and autoimmune sclerosing cholangitis

M.B. Dyba; V.S. Berezenko; O.M. Tkalyk; Kh.Z. Dmytrenko

doi:10.26641/2307-0404.2025.3.340760

Authors

M.B. Dyba SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Platona Maiborody str., 8, Kyiv, 0405, Ukraine https://orcid.org/0000-0002-9463-7867
V.S. Berezenko SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Platona Maiborody str., 8, Kyiv, 04050; Bogomolets National Medical University, Beresteyskiy ave., 34, Kyiv, 03057, Ukraine https://orcid.org/0000-0002-3777-5251
O.M. Tkalyk SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Platona Maiborody str., 8, Kyiv, 0405, Ukraine https://orcid.org/0000-0002-5449-8399
Kh.Z. Dmytrenko SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Platona Maiborody str., 8, Kyiv, 0405, Ukraine https://orcid.org/0000-0002-6720-6674

DOI:

https://doi.org/10.26641/2307-0404.2025.3.340760

Keywords:

autoimmune hepatitis, autoimmune sclerosing cholangitis, treatment, biochemical response, shear wave elastography

Abstract

Autoimmune liver diseases in children, particularly autoimmune hepatitis and autoimmune sclerosing cholangitis, represent a challenging clinical issue due to their variable clinical course, diagnostic complexity, and suboptimal therapeutic efficacy. Despite common pathogenetic mechanisms, including impaired immune regulation, association with class II major histocompatibility complex molecules, chronic inflammation, and fibrosis, these conditions differ significantly in clinical presentation, treatment response, and prognosis. The incidence of autoimmune hepatitis in children is 3-6 cases per 100,000, whereas autoimmune sclerosing cholangitis is rarer, diagnosed in 0.2-1.5 cases per 100,000 children. The primary therapeutic goal is achieving biochemical remission and preventing fibrosis progression. A lack of biochemical improvement within the first 6–12 months of treatment is associated with poorer outcomes; however, clear algorithms for intensifying therapy have not yet been established. Standardizing biochemical markers for assessing treatment effectiveness remains a relevant issue. The aim of this study was to perform a comparative analysis of immunosuppressive therapy effectiveness in children with autoimmune hepatitis and autoimmune sclerosing cholangitis based on the evaluation of biochemical response rates. We conducted a retrospective analysis of immunosuppressive therapy effectiveness during the first 12 months in children and adolescents with autoimmune liver diseases treated in the pediatric hepatology department for 2016 to 2024. Two groups were formed: group 1 – autoimmune hepatitis (n=84), and group 2 – autoimmune sclerosing cholangitis (n=38). At disease onset, children in group 2 exhibited higher gamma-glutamyltransferase levels (p=0.003) and more frequently had inflammatory bowel disease (68% vs. 9.5%, p<0.0001). Early biochemical response was achieved in 4 weeks of therapy in 86% of group 1 and 82% of group 2, respectively (p>0.05). In 6 months, complete biochemical response was observed in 50% of group 1 and 32% of group 2 (p=0.07). In 12 months, complete response rates were 73% and 47%, respectively (p=0.007). Elastography indicated a significant decrease in liver stiffness in both groups (p<0.0001 and p=0.002, respectively). Thus, children with autoimmune sclerosing cholangitis demonstrate significantly lower efficacy of immunosuppressive therapy within the first 12 months compared to autoimmune hepatitis. Liver stiffness measurement by elastography may serve as an additional objective criterion for evaluating treatment effectiveness.

References

Kemme S, Mack CL. Pediatric autoimmune liver diseases: autoimmune hepatitis and primary sclerosing cholangitis. Pediatr Clin North Am. 2021;68(6):1293-307. doi: https://doi.org/10.1016/j.pcl.2021.07.006

Nastasio S, Mosca A, Alterio T, Sciveres M, Maggiore G. Juvenile autoimmune hepatitis: Recent advances in diagnosis, management and long-term outcome. Diagnostics. 2023;13:2753. doi: https://doi.org/10.3390/diagnostics13172753

Di Giorgio A, Vergani D, Mieli-Vergani G. Cutting edge issues in juvenile sclerosing cholangitis. Dig Liver Dis. 2022;54:417-27. doi: https://doi.org/10.1016/j.dld.2021.06.028

Ricciuto A, Kamath BM, Hirschfield GM, Tri-vedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? J Hepatol. 2023;79(2):567-75. doi: https://doi.org/10.1016/j.jhep.2023.02.030

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the mana-gement of autoimmune hepatitis. J Hepatol. 2025;83(2):453-501. doi: https://doi.org/10.1016/j.jhep.2025.03.017

Ramonet M, Ramirez-Rodriguez N, Chávez FÁ, Arregui MC, Boldrini G, Osorio VB, et al. Autoimmune hepa¬titis in pediatrics: A review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Arch Argent Pediatr. 2022;120:281-7. doi: https://doi.org/10.5546/aap.2022.eng.281

Ludz C, Stirnimann G, Semela D, Mertens J, Kremer AE, Sinnreich MF, et al. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: A retrospective and prospective cohort study. Swiss Med Wkly. 2023;153:40102. doi: https://doi.org/10.57187/smw.2023.40102

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. doi: https://doi.org/10.1002/hep.31065

Wang P, Yuksel M, Gabeta S, Graham J, Hussain M, Blackmore LJ, et al. HLA alleles predisposing to autoimmunity are linked to impaired immunoregulation in patients with juvenile autoimmune liver disease and in their first-degree relatives. J Autoimmun. 2025;154:103436. doi: https://doi.org/10.1016/j.jaut.2025.103436

Sutton H, Tayler R, Chalmers I, Cowieson J, Fraser K, Henderson P, et al. The epidemiology of pediatric autoimmune hepatitis in Scotland. JPGN Rep. 2022;3:e223. doi: https://doi.org/10.1097/pg9.0000000000000223

Warner S, Rajanayagam J, Russell E, Lloyd C, Ferguson J, Kelly DA, et al. Biliary disease progression in childhood-onset autoimmune liver disease: A 30-year follow-up into adulthood. JHEP Rep. 2024;6:100901. doi: https://doi.org/10.1016/j.jhepr.2023.100901

Anderson CM, Welle CL, Ludwig DR, Anderson MA, Khot R, Itani M, et al. Autoimmune disorders of the liver and biliary tract. Radiographics. 2025;45:e240126. doi: https://doi.org/10.1148/rg.240126

Mieli‐Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease. J Pediatr Gastroenterol Nutr. 2018;66:345-60. doi: https://doi.org/10.1097/MPG.0000000000001801

Ricciuto A, Kamath BM, Hirschfield GM, Trivedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? J Hepatol. 2023;79:567-75. doi: https://doi.org/10.1016/j.jhep.2023.02.030

Stevens JP, Gupta NA. Recent insights into pediatric primary sclerosing cholangitis. Clin Liver Dis. 2022;26:489-519. doi: https://doi.org/10.1016/j.cld.2022.03.009

Di Giorgio A, Hadzic N, Dhawan A, Deheragoda M, Heneghan MA, Vergani D, et al. Seamless management of juvenile autoimmune liver disease: Long-term medical and social outcome. J Pediatr. 2020;218:121-129.e3. doi: https://doi.org/10.1016/j.jpeds.2019.11.028

Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoim-mune Hepatitis Group. J Hepatol. 2022;76:841-9. doi: https://doi.org/10.1016/j.jhep.2021.12.041

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: https://doi.org/10.1001/jama.2013.281053

Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: Review of histologic features included in the simplified criteria proposed by the International Autoimmune Hepatitis Group and proposal for new histologic criteria. Mod Pathol. 2017;30:773-83. doi: https://doi.org/10.1038/modpathol.2016.267

Lohse AW, Sebode M, Bhathal PS, Clouston AD, Dienes HP, Jain D, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int. 2022;42(7):1375-89. doi: https://doi.org/10.1111/liv.15230

Riffenburgh RH. Statistics in Medicine. 4th ed. Amsterdam: Academic Press, Elsevier; 2020. ISBN: 978-0-12-820297-5

Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2018;68:754-63. doi: https://doi.org/10.1016/j.jhep.2017.11.020

Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: Epidemiology and natural history. Hepatology. 2013;58:1392-400. doi: https://doi.org/10.1002/hep.26454

Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis. 2021;53(11):1381-93. doi: https://doi.org/10.1016/j.dld.2021.05.03

Plagiannakos CG, Hirschfield GM, Lytvyak E, Roberts SB, Ismail M, Gulamhusein AF, et al. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024;81:227-37. https://doi.org/10.1016/j.jhep.2024.03.021

Deneau MR, El‐Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, et al. The natural history of primary sclerosing cholangitis in 781 children: A multi-center, international collaboration. Hepatology. 2017;66:518-27. doi: https://doi.org/10.1002/hep.29204

Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol Dietol. 2009;55:53-70. PMID: 19212308

Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16‐year prospective study. Hepatology. 2001;33:544-53. doi: https://doi.org/10.1053/jhep.2001.22131

Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, et al. Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17:2068-2075.e2. doi: https://doi.org/10.1016/j.cgh.2018.12.035

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, et al. Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months. Clin Gastroenterol Hepatol. 2020;18:1609-1617.e4. doi: https://doi.org/10.1016/j.cgh.2019.11.013

Dyba MB, Berezenko VS. [Possibilities of shear wave elastography in the diagnosis of liver fibrosis and monitoring of autoimmune liver diseases in children]. Modern Pediatr. 2023;8(136):34-41. Ukrainian. doi: https://doi.org/10.15574/SP.2023.136.34